INTRODUCTION
============

Idiopathic pulmonary fibrosis (IPF) is the commonest of the idiopathic interstitial pneumonias. Whilst its cause is unknown, it results in progressive fibrosis of the alveolar walls and severe impairment of lung function which is usually fatal ([@b21-jer-15-1-160]). The histological pattern observed in IPF is described as usual interstitial pneumonia (UIP) and is characterized by excess extracellular matrix within the alveolar interstitium, which typically demonstrates spatial and temporal heterogeneity. Thus, areas of relatively normal lung are interspersed with areas of mild fibrosis, yet other areas show extensive fibrosis with subpleural cysts, termed honeycombing. The latter can be demonstrated using computed tomography scanning of the thorax and is typically worse at the posterior lung bases. The median survival for patients diagnosed with IPF is 2.5 to 3.5 years, although the range is wide ([@b15-jer-15-1-160]); some follow a slowly declining trajectory over many years whilst others have a rapidly progressive course. Whilst new therapies that slow the decline in lung function have recently been recommended for IPF ([@b21-jer-15-1-160]) there is still no cure. Interestingly, the histological and radiological changes of UIP can also be observed in some patients with collagen vascular disease such as rheumatoid disease and this is associated with an increased all-cause mortality ([@b10-jer-15-1-160]). Patients with UIP present with symptoms of increasing breathlessness and fatigue which causes them difficulty conducting day-to-day activities and reduces quality of life ([@b9-jer-15-1-160]).

The primary goal of physical exercise-based pulmonary rehabilitation (PR) is to "restore patients to the highest possible functional state" ([@b1-jer-15-1-160]). Whilst PR can improve exercise performance and lung function in other forms of chronic lung disease (such as chronic obstructive pulmonary disease \[COPD\]) ([@b22-jer-15-1-160]), evidence of its influence on IPF patients is limited ([@b6-jer-15-1-160]) but growing ([@b8-jer-15-1-160]; [@b25-jer-15-1-160]). [@b8-jer-15-1-160] reported improved 6-min walk test distances (6MWD), health-related quality of life (HRQoL) and symptom severity in interstitial lung disease (ILD) patients (including 61 IPF patients) after eight weeks of PR (although these subsequently declined over the following 6 months). [@b25-jer-15-1-160] also observed substantial improvements in symptom severity, HRQoL and physical function (6MWD and peak power during cycle ergometry) in ILD patients (including 21 IPF) after around 30 rehabilitation sessions. Both of these studies noted that patients with the most severe functional restriction at baseline benefited the most from rehabilitation. Further research is needed to investigate the mechanisms by which these functional improvements are achieved, and it seems reasonable to expect a substantial role of the cardiovascular system in this regard. Whilst it would not be expected that PR would modify the irreversible structural changes of fibrotic lungs, it is reasonable to consider that it might influence the cardiovascular system. We previously showed that IPF patients' peak VO~2~ values were half those of similarly aged healthy individuals, whilst their peak heart rates (HRs) were 20% lower and their kinetic HR responses to heavy intensity exercise were 2.5 times slower ([@b17-jer-15-1-160]). These results provide evidence of reduced tissue oxygen utilization following the onset of exercise in people with UIP, which in large part results from impeded central (cardiovascular) oxygen delivery. It would therefore be useful to determine whether a physical rehabilitation programme could improve systemic oxygen delivery (and peripheral muscle oxygen availability) in people with UIP.

HR dynamics are thought to provide a good proxy for the response of cardiac output and muscle blood flow to increased metabolic demand ([@b16-jer-15-1-160]; [@b27-jer-15-1-160]), albeit they do not account for the contribution of stroke volume in meeting this demand. One way to determine HR responsiveness is to measure the variation in beat-to-beat duration of the cardiac cycle or HRV ([@b14-jer-15-1-160]). This technique has been widely used to estimate the influences of the autonomic nervous system (ANS) on HR in various populations. However, caution must be applied when HRV is used to determine an individual's capacity to increase or decrease HR. Firstly, because HRV must be determined during steady-state conditions and for extended periods. Hence, it cannot provide an overall measure of the range of cardiac dynamics that occur across multiple states or that are transient in nature. Secondly, the use of HRV as an independent measure of sympathetic and parasympathetic control is not straightforward ([@b14-jer-15-1-160]). An alternative measure of cardiac dynamics that avoids these restrictions is the use of phase-rectified signal averaging (PRSA) ([@b5-jer-15-1-160]). This method yields averaged beat-to-beat cardiac intervals (RR) time series that separately characterize all HR modulations that result in accelerations and decelerations.

It is known that individuals with COPD have a degree of cardiac autonomic dysfunction, reflected by altered HR variability (HRV) during rest and exercise ([@b4-jer-15-1-160]) but with a normal diurnal variation ([@b12-jer-15-1-160]). They also have a tendency towards reduced PRSA-derived cardiac dynamic capacities that are ameliorated with oxygen therapy ([@b11-jer-15-1-160]). However, as far as we are aware, neither HRV nor cardiac acceleration/deceleration capacities have been evaluated in individuals with UIP. A comparison of these variables before and after physical rehabilitation might indicate whether they would benefit from such interventions in terms of improved cardiac responsiveness to everyday activities.

In this context, the aim of this study was to determine the influence of an 8-week, exercise-based PR programme on measures of cardiac autonomic control in patients with UIP. Specifically, we sought to quantify HRV and indices of cardiac acceleration and deceleration capacity for these individuals during periods of rest and exercise.

MATERIALS AND METHODS
=====================

Participants
------------

The study was performed in accordance with the Declaration of Helsinki. Ethical approval to conduct the study was obtained (approval number: 16/WA/0272) from Wales Research Ethics Committee 6, part of the UK Health Departments' Research Ethics Service. Approval and permission to execute the study was obtained from the local health board (Abertawe Bro Morgannwg University Health Board). Recruitment was led by a consultant chest physician, who informed eligible patients about the study (including its purpose, protocol, expected commitment, and the possible risks of involvement). Patients attending the Interstitial Lung Disease Clinic at Moriston Hospital, Swansea, who had been diagnosed with UIP (either IPF or UIP associated with rheumatoid disease) by a Multi-Disciplinary Team, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines ([@b20-jer-15-1-160]) were eligible to participate. All recruited individuals provided their written informed consent to participate in the study. Eighteen individuals (13 male, 5 female) agreed to participate in the study but three males later withdrew from the rehabilitation programme for personal reasons. Patients continued with their usual medication regimes whilst participating in the study. The patients' demographics are shown in [Table 1](#t1-jer-15-1-160){ref-type="table"}.

Exclusion criteria
------------------

-   Respiratory infection within the previous 2 months.

-   Known coronary or valvular heart disease.

-   Any other serious comorbid condition (e.g., emphysema, uncontrolled diabetes, renal disease) Significant hypoxia (oxygen saturation below 85%) when breathing air and undergoing conventional screening for a PR programme.

-   Musculoskeletal problems that would make it impossible to exercise.

-   Current smokers.

Experimental protocol
---------------------

Participants were asked to visit the lung function laboratory at Morriston Hospital, Swansea, for baseline physiological assessment. They were also asked to not consume alcohol for 24 hr before each test day, to not consume caffeine for 6 hr prior to the scheduled tests, but otherwise to have eaten and consumed fluids as normal. All tests were conducted on the same time of the day ±1 hr.

Participants undertook a 6-min walk test to determine their functional (walking) capacity (6MWD), in line with ATS guidelines ([@b3-jer-15-1-160]). On a separate day they were asked to complete an incremental exercise test on a stationary bicycle (ergometer) (VIAsprint150P Ergometer, Vyaire Medical, Mettawa, IL, USA) in accordance with methods described by [@b2-jer-15-1-160]. Participants first completed 3 min of cycling with zero resistance, after which the work rate was increased at a rate of 10--15 W/min, depending on the individual's age-predicted maximum workload. They were asked to maintain a cadence of 55--60 rpm at all times and to continue cycling until they reached their limit of exercise tolerance; the test was stopped by the researchers if a patient desaturated to an oxygen level below 85%. Throughout the test, which included 6-min periods of rest before and after exercise, a continuous Holter ECG was recorded (Pathfinder/Lifecard Digital CF system; Spacelabs Healthcare Ltd., Hertford, UK), providing ECG data with a 1,024-Hz sampling frequency, 12-bit resolution and a sample accuracy of 2.5 μV. The ECG leads were positioned in the 'modified V5, CC5, modified V5R' electrode configuration. Patients were also asked to breathe through a facemask which allowed us to sample the air that they inspire/expire using an online respiratory gas analyser (MGC Ultima CardiO2; MGC Diagnostics, St Paul, MN, USA) and blood oxygen saturation was continuously monitored (Nonin Model 7500; Nonin Medical Inc., Plymouth, MN, USA).

Following baseline measurements participants began a 6-week PR programme (two sessions per week, 2 hr per session). This programme consisted of 10 min of 'warming up' (20 sets of 'marching on the spot,' 'heal digs,' 'knee lifts,' 'shoulder rolls,' 'knee bends,' and 'high knees') followed by a range of strength training exercises ('bicep curls,' 'triceps extension,' 'dumbbell press,' 'dumbbell fly,' 'leg extension,' and 'dumbbell squats') and cardiovascular exercises (choice of treadmill, bicycle ergometer or cross-trainer exercise). Each patient was asked to choose a weight that they could safely handle at the beginning of the rehabilitation for use in each exercise, and they were encouraged to increase their weights on each day of rehabilitation as the programme progressed. For the cardiovascular exercise patients were asked to select a mode of exercise with which they were comfortable, which was maintained throughout the programme but with increasing workload (resistance) as rehabilitation progressed. The strength exercises lasted 5 min each and the cardiovascular exercise lasted 10 min, followed by a 10-min cool-down period (which included sets of 'hip flexor stretch,' 'thigh stretch,' 'calf stretch,' and 'lower back stretch'). Upon completion of the rehabilitation programme patients were asked to return to the hospital for repeat physiological and functional assessments.

Data analysis
-------------

ECG recordings were assessed for quality by human observation using the Pathfinder system, primarily to verify the absence of excessive noise or artefact. Beat-to-beat cardiac intervals (RR) were then measured automatically by the Pathfinder system (using a proprietary algorithm) and any spurious data points (artefacts) were removed manually prior to subsequent analysis. The RR data were then analysed using the Kubios HRV software package (version 3.1) ([@b23-jer-15-1-160]) in three separate but contiguous sections covering the pre-exercise (rest), exercise, and recovery (postexercise) stages. The RR data within each of these sections was first detrended using the 'Smooth priors' function (Lambda=500). HR and HRV variables were next quantified according to the European Society of Cardiology Task Force guidelines ([@b24-jer-15-1-160]): (a) RMSSD (square root of the mean squared differences of successive RR intervals), (b) SDRR (standard deviation of RR intervals), (c) total power (TP; total amount of 'power' \[variance\] in the bandwidth \~0 to 0.4 Hz), (d) VLF (very low frequency power, in the bandwidth 0.003--0.1 Hz), (e) LF (low-frequency power in the bandwidth 0.04--0.15 Hz), (f) HF (high-frequency power in the bandwidth 0.15--0.4 Hz), (g) LFn (normalised low frequency power): LFn=LF/(TP--VLF), (h) HFn (normalised high-frequency power): HFn=HF/(TP--VLF), and (i) the ratio LF/HF.

We used the PRSA procedure ([@b5-jer-15-1-160]) to quantify the acceleration capacity (AC) and deceleration capacity (DC): (a) multiple DC and AC 'anchor points' were identified, respectively, as those RR intervals longer than or shorter than the preceding RR interval; (b) a truncated RR time series was defined around each of the anchor points (a 61-point series, including 30 points preceding and following the anchor point); (c) the truncated RR time-series were aligned (separately for DC and AC anchor points) and averaged to form the PRSA time-series; (d) DC and AC were calculated as \[(X~0~+X~1~)--(X~−1~+X~−2~)\]/4, where X~0~ and X~1~ are the averaged RR intervals at the anchor point and the immediately following point, and X~−1~ and X~−2~ are the two averaged RR intervals immediately preceding the anchor point. Group mean Acceleration and Deceleration vectors (used for visualization) were calculated after standardising the individual RR time-series (to minimize interindividual differences in resting RR)--this was performed by subtracting the mean of the 12 RR intervals immediately preceding interval X~−2~ from each RR value in the time-series.

The rates of oxygen uptake (VO~2~) and carbon dioxide production (VCO~2~) and minute ventilation (Ve) were measured from the breath-by-breath respiratory gas data using the Breeze computer software (Breeze Software 6.4.1, Medical Graphics, St Paul, MN, USA). Forced expiratory volume in 1 sec and forced vital capacity were measured using the spirometry test function of the online respiratory gas analyser. The maximum rate of oxygen uptake (VO~2max~) was determined by averaging the VO~2~ values from the last 10 sec before the limit of exercise was reached.

Statistical analysis
--------------------

Matlab (version 2017b, The Mathworks, Cambridge, UK) was used to perform descriptive statistical analysis and to evaluative the nature of their distributions. The One-Sample Kolomogorov--Smirnov Test was used to test the null hypothesis that each group-wide HRV and PRSA-derived variable belonged to a standard normal distribution. If this assumption was violated then the influence of the rehabilitation intervention on each variable was assessed using Wilcoxon Signed Rank tests, and data were presented as median (M) and lower/upper quartile (Q1, Q2) values. One-sample Kolmogorov--Smirnov tests showed that none of the quantified variables were normally-distributed. Consequently the Wilcoxon Signed-rank test was used to assess the influence of PR for each variable. Statistical significance was assumed at the *P*\<0.05 level.

RESULTS
=======

Values for 6MWD and maximum rate of oxygen uptake before and after PR are shown in [Table 2](#t2-jer-15-1-160){ref-type="table"}. For the group as a whole, 6MWT performance was poorer following PR (*P*=0.037, *z*=−2.09, ES= 0.41) whilst VO~2max~ was unchanged (*P*=0.93, *z*=0.09, ES=0.02).

The HRV indices calculated pre- and postintervention for the pre-exercise (Rest), exercise (Ex), and recover (Rec) periods are shown in [Table 3](#t3-jer-15-1-160){ref-type="table"}. This shows that the intervention did not influence any of the HRV variables during the Pre-Exercise (*P*=0.14--0.99) or Exercise (*P*=0.12--0.76) states. HR was greater (and RR was lower) postintervention during the Recovery state (*P*=0.036, *z*=−2.10, ES=0.38) and both HFn (*P*=0.069, *z*=−1.82, ES= 0.33) and LF/HF (*P*=0.047, *z*=1.99, ES=0.36) showed trends towards greater high-frequency dominance during recovery postintervention (other variables: *P*=0.21--0.72). The relative changes in HRV (HR, SDNN, RMSSD, LFn, and TP) following the intervention (expressed as percentages) are shown in [Fig. 1](#f1-jer-15-1-160){ref-type="fig"} (the remaining variables are largely redundant for this purpose as they are closely related to these five variables).

To illustrate the PRSA averaging procedure, [Fig. 2](#f2-jer-15-1-160){ref-type="fig"} shows the group mean (±standard error of the mean) of the normalized RR time-series around the identified acceleration and deceleration turning-points. [Fig. 3](#f3-jer-15-1-160){ref-type="fig"} is a box-and-whisker plot of the AC and DC pre- and postintervention: the median (lower quartile, upper quartile) AC was −2.7 msec (−1.8, −5.3) preintervention and −3.2 msec (−2.5, −4.9) postintervention; the DC was 2.3 msec (1.8, 4.8) preintervention and 3.2 msec (2.5, 4.3) postintervention. Wilcoxon Signed Rank tests revealed no influence of the intervention on either AC (*P*=0.53, *z*=0.63, ES=0.11) or DC (*P*=0.73, *z*=−0.35, ES=−0.06) indices.

DISCUSSION
==========

We believe this is the first study to investigate the effect of a PR programme on HR responsiveness in people with UIP. We found that HR was elevated by 11%--18% during Exercise and Recovery states postrehabilitation, suggesting that participants' heart function (HR increase in response to exercise) was improved postrehabilitation. Statistically, HRV was not altered by the rehabilitation intervention during any of the three stages of our protocol (rest, exercise, recovery). However, we did observe substantial relative (post- vs. prerehabilitation) changes that are worthy of note: (a) a greater pre-exercise parasympathetic influence (RMSSD elevated by 70%), (b) greater sympathetic and parasympathetic influences during Exercise (SDNN and RMSSD elevated by 75%), and (c) a greater parasympathetic influence during postexercise (RMSSD elevated by 68%, HFn elevated by 24%). Whilst the numbers are small, we found that neither the acceleration index nor the deceleration index were statistically influenced by the intervention. However, we did observe trends for relative (post- vs. prerehabilitation) improvements in these indices (changes of 19% and 38%, respectively).

Our qualitative observations of altered HRV following physical rehabilitation suggest that this intervention had a positive influence on patients' cardiac autonomic regulation profiles. Conditions of stress (such as moderate physical exercise, a change in posture from supine to standing or mental processing tasks) alter the sympatho-vagal balance towards a more sympathetic-dominant state; this is reflected in frequency-domain HRV by a relative increase in LF power (reduction in HF power) and a reduction in TP, with a corresponding relative increase in SDNN (reduction in RMSSD) in time-domain HRV ([@b24-jer-15-1-160]). At high work rates LF, HF and TP components of HRV are diminished compared with rest and lower work rates ([@b7-jer-15-1-160]; [@b14-jer-15-1-160]). During progressive maximal exercise LF and HF are reduced exponentially ([@b19-jer-15-1-160]; [@b26-jer-15-1-160]) and [@b13-jer-15-1-160] showed that the decay constants of HRV indices in each bandwidth are linearly related to maximal work rate. In the present study, the 70% postintervention increase in RMSSD during rest suggests that patients' resting cardiac autonomic states became more typical of the relaxed (parasympathetic-dominant) states displayed in healthy people. Increases of similar magnitude (75%) in RMSSD and SDNN during exercise indicate that patients were working at lower relative intensities following the intervention (they found the same activity easier to perform so the exponential-reduction in HRV power was not as great). Finally, following the intervention patients displayed a large (68%) increase in RMSSD during recovery, and this faster return to the pre-exercise (parasympathetic-dominant) state likely reflects improved cardiac 'fitness'.

We previously observed significantly reduced values for AC and DC in older compared with younger healthy individuals: older (mean age 66 years; AC=−5 to −7 msec; DC=4.5 to 6.5 msec) and younger (mean age 21 years; AC=−10 to −12; DC=8 to 10 msec) ([@b11-jer-15-1-160]). In that study patients with COPD had qualitatively reduced values (AC diminished by 4--6 msec; DC diminished by 2--3 msec) compared with similarly aged healthy people. A further study by our group added to these data, showing that AC and DC are reduced in middle-aged (mean 45 years) compared with younger (mean 24 years) healthy individuals (mean values AC=−8.4/−10.3 and DC=7.6/9.5 msec, respectively) and that both AC and DC are enhanced in aerobically superior individuals ([@b18-jer-15-1-160]). The AC and DC values observed for patients with IPF in the present study (AC=−2.7 to −3.2 msec; DC=2.3 to 3.2 msec) are around 50% lower than those of similarly aged healthy people and are similar to those of individuals with COPD who have not received oxygen therapy. Visualisation of the RR time-series around the identified acceleration and deceleration anchor-points enabled the following observations: (a) acceleration anchor-points occurred at larger RR values after rehabilitation, (b) deceleration anchor-points occurred at smaller RR values after rehabilitation, (c) immediately post-anchor acceleration was greater (RR values achieved were smaller) after rehabilitation, and (d) immediate post-anchor deceleration was greater (RR values achieved were larger) after rehabilitation. These observations mean that, following rehabilitation: (a) HR was allowed to reach lower values before triggering a larger tachycardic response and (b) HR was allowed to reach higher values before triggering a larger bradycardic response. We suggest that these results provide evidence that the physical rehabilitation intervention may have improved the dynamic range of HR responsiveness in our patients with UIP. We further speculate that this would have enhanced patients' physical function during everyday tasks (being mindful that the AC and DC indices were calculated as an ensemble across each of the three physiological states in our protocol).

The diminished cardiac acceleration and deceleration capacities in UIP patients reflect the autonomic dysfunction that is also indicated qualitatively by the HRV variables for this group of individuals. Postintervention improvements in AC and DC indices appear to reflect the observed shift towards 'healthy' HRV values for these patients. Taken together, these changes suggest that physical rehabilitation had a positive 'normalising' influence on cardiac autonomic modulation of HR in people with UIP.

When considering the results reported here we must be mindful of potential confounders relating to both the UIP patient population and also our study design. Whilst we consider our sample of 15 patients to be representative of people with UIP, one limitation of this study is the relatively small number of participants, which reduced the statistical power of our analyses. We considered the influence of potential confounders on the ANS and thus on the measured parameters. We therefore excluded patients who had comorbid conditions that might influence cardiac or ANS function. However, we were also mindful of the potential influence of too strict a set of exclusion criteria on both recruitment and the applicability of our results to a wider population or people with UIP. With this in mind we took the decision to not exclude individuals with controlled diabetes from the study: five (27%) of our patient cohort were taking medication to treat type II diabetes. Furthermore, patients acted as their own controls and care was taken to ensure that the only change between the monitoring days was the intervening rehabilitation intervention.
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###### 

Patient demographics

  Patient ID   Age (yr)   Gender   BMI (kg/m^2^)   FEV~1~, L (%)   FVC, L (%)
  ------------ ---------- -------- --------------- --------------- ------------
  P01          72         M        36.7            1.92 (67)       2.33 (62)
  P02          73         F        47.7            1.46 (82)       1.66 (77)
  P03          74         M        26.3            2.34 (78)       2.78 (63)
  P04          67         F        34              1.48 (75)       1.81 (76)
  P05          78         M        32.7            2.93 (130)      3.95 (131)
  P06          60         F        32              2.73 (88)       3.49 (89)
  P07          68         M        32.3            2.53 (79)       3.22 (74)
  P08          83         M        28.7            2.21 (85)       2.90 (82)
  P09          73         M        23.1            1.93 (63)       3.13 (52)
  P10          75         M        20.8            2.22 (93)       3.37 (107)
  P11          68         F        30.4            1.77 (60)       2.12 (53)
  P12          72         M        25.3            2.00 (63)       1.46 (61)
  P13          64         F        30.1            1.12 (55)       1.46 (59)
  P14          65         M        24.5            2.50 (78)       3.25 (78)
  P15          55         M        29.8            NA              NA

BMI, body mass index; FEV~1~, age-predicted forced expiratory volume in 1 sec; FVC, age-predicted forced expiratory volume; NA, not available.

###### 

Six-minute walk distance (6MWD) and maximum rate of oxygen uptake (VO~2max~) pre- and postpulmonary rehabilitation

  Patient ID   6MWD (m)   VO~2max~ (mL/kg/min)          
  ------------ ---------- ---------------------- ------ ------
  P01          370        362                    14.9   15.2
                                                        
  P02          200        304                    10.0   8.4
                                                        
  P03          290        430                    18.7   17.1
                                                        
  P04          358        373                    13.1   12.8
                                                        
  P05          181        300                    14.6   13.5
                                                        
  P06          384        480                    16.0   12.5
                                                        
  P07          407        427                    18.3   19.3
                                                        
  P08          300        322                    15.1   9.6
                                                        
  P09          222        NA                     14.3   12.8
                                                        
  P10          457        440                    28.4   26.2
                                                        
  P11          NA         NA                     12.5   15.4
                                                        
  P12          NA         NA                     14.0   18.2
                                                        
  P13          310        304                    9.5    16.9
                                                        
  P14          NA         NA                     14.3   17.1
                                                        
  P15          419        NA                     13.9   15.3

PR, pulmonary rehabilitation; NA, not available.

###### 

Heart rate variability indices pre- and postpulmonary rehabilitation

  Variable                   HR (bpm)   RR (msec)   SDNN (msec)   RMSSD (msec)   VLF (msec^2^)   LF (msec^2^)   HF (msec^2^)   LFn (%)   HFn (%)   LF/HF   TP (msec^2^)
  ---------- ------- ------- ---------- ----------- ------------- -------------- --------------- -------------- -------------- --------- --------- ------- --------------
  Pre-PR     Rest    M       85.4       702.9       14.7          13.6           6.7             57.1           19.7           56.7      43.0      1.3     94.4
  Q1         74.3    586.0   8.4        11.8        3.1           10.6           11.9            41.4           30.4           0.7       35.2              
  Q3         102.5   816.0   27.7       18.3        37.8          162.6          72.9            67.1           57.3           2.3       249.3             
  Ex         M       101.0   594.2      13.5        19.9          2.9            20.0            20.0           39.6           59.4      0.7       63.0    
  Q1         84.2    536.4   9.4        13.3        1.2           6.6            7.6             27.5           39.4           0.4       22.0              
  Q3         111.9   712.0   32.9       40.9        20.9          191.4          117.8           60.1           72.0           1.5       347.2             
  Rec        M       94.0    638.1      16.0        15.6          18.7           60.9            48.6           47.5           52.3      0.9       136.0   
  Q1         86.5    548.0   11.2       11.1        5.9           34.1           10.5            33.1           15.8           0.5       50.3              
  Q3         109.6   693.3   34.6       50.8        41.0          322.6          222.9           84.0           66.4           5.6       606.3             
                                                                                                                                                           
  Post-PR    Rest    M       86.6       692.7       15.0          23.1           9.3             72.4           53.2           61.6      38.2      1.6     153.9
  Q1         79.4    641.2   12.3       15.1        4.2           42.2           15.3            39.5           19.6           0.6       93.1              
  Q3         93.6    755.3   20.6       31.9        42.2          147.9          123.4           80.2           59.6           4.1       210.4             
  Ex         M       112.5   549.4      23.6        34.9          7.1            45.1            73.8           36.3           62.3      0.5       119.6   
  Q1         93.2    522.3   11.0       19.7        2.6           20.5           8.7             26.0           43.6           0.4       39.9              
  Q3         115.4   638.8   31.3       43.6        13.9          110.4          316.8           56.3           73.4           1.3       527.1             
  Rec        M       110.9   541.2      16.5        26.2          5.3            60.5            43.2           34.4           64.9      0.5       143.1   
  Q1         90.6    513.3   12.5       17.8        2.2           15.5           11.7            30.0           32.7           0.4       46.1              
  Q3         116.9   665.9   30.0       43.3        12.2          146.4          173.2           67.1           69.2           2.2       349.0             

Median (M) and the lower (Q1) and upper (Q3) quartile values are shown, separately for the pre-exercise (Rest), exercise (Ex) and recover (Rec) periods.

HR, heart rate; RR, beat-to-beat cardiac intervals; SDNN, standard deviation of the normal-to-normal (sinus origin) cardiac intervals; RMSSD, square root of the mean squared differences of successive RR intervals; VLF, very low frequency; LF, low frequency; HF, high frequency; LFn, normalized low frequency; HFn, normalized high frequency; LF/HF, low frequency/high frequency; TP, total power; PR, pulmonary rehabilitation.
